Why Abzena?
Our focused approach.
With a solid foundation in analytical services and leading cell line development (CLD) platform, Abzena provide integrated mammalian CDMO services from discovery, through CLD to clinical and commercial manufacturing.
To accelerate your molecule to the next milestone, Abzena offer biopharmaceutical services and solutions that deploy the best technologies, shorten lead times, and implement effective risk mitigation strategies throughout the stages of preclinical development to clinical and commercial manufacturing.
Our technologies and over 20 years of experience allow us to efficiently develop and manufacture biotherapeutics such as monoclonal antibodies (mAbs), bispecific and multispecific antibodies (BsAbs & MsAbs), fusion proteins, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs) and more.
As your molecule moves forward through research and early development into clinical and commercial manufacturing, who can you count on to start smart and get you across the finish line? Abzena is committed to your success, and to moving medicine forward.
Leverage our end-to-end integrated services and knowledge to quickly and efficiently develop and manufacture any type of mammalian derived biopharmaceuticals. Access our corporate brochure to learn why we are considered to be the leading bioconjugate, antibody-drug conjugate (ADC), and complex biologics CDMO + CRO.
We develop and manufacture mammalian-derived biopharmaceuticals in state-of-the-art, integrated cGMP facilities.
We enable you to bring life-changing medicines to patients in need faster. Let’s talk and move medicine forward.